Community-acquired respiratory tract infections caused by resistant pneumococci: Clinical and bacteriological efficacy of the ketolide telithromycin

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 4, 2003, Pages 947-955

  Fogarty, Charles M ^a   Kohno, Shigeru ^b   Buchanan, Patricia ^c   Aubier, Michel ^d   Baz, Malik ^e  

^a Spartanburg Pharmaceutical Research ^*  (United States)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c River Road Medical Group   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e ABM Research Institute   (United States)

Author keywords

Bacteriological efficacy; Clinical efficacy; Ketolide; Resistant S. pneumoniae; Telithromycin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFUROXIME AXETIL; CLARITHROMYCIN; ERYTHROMYCIN; KETOLIDE; MACROLIDE; PENICILLIN G; TELITHROMYCIN; TROVAFLOXACIN;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; ERADICATION THERAPY; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; JAPAN; KETOLIDES; MACROLIDES; MALE; MIDDLE AGED; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 0037398758     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg153     Document Type: Article

References (50)

1. Schwartz, R. (1994). The diagnosis and management of sinusitis. Nurse Practitioner 19, 58-63.
2. Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Jr, Musher, D. M. & Fine, M. J. (2000). Practice guidelines for the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 31, 347-82.
3. Murray, O. L. & Lopez, A. D. (1998). The Global Burden of Disease: a Comprehensive Assessment of Mortality and Risk Factors in 1990 and Projected to 2020. Harvard University Press, Boston, MD, USA.
4. Bartlett, J. G. & Mundy, L. M. (1995). Community-acquired pneumonia. New England Journal of Medicine 333, 1618-25.
5. Lim, W. S., Macfarlane, J. T., Boswell, T. C. J., Harrison, T. G., Rose, D., Leinonen, M. et al. (2001). Study of community-acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 56, 296-301.
6. British Thoracic Society. (2001). BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 56, Suppl. 4, IV1-64.
7. Ball, P. (1995). Epidemiology and treatment of chronic bronchitis. Chest 108, Suppl., 43S-52S.
8. Brook, I., Gooch, W. M., Jenkins, S. G., Pichichero, M. E., Reiner, S. E., Sher, L. et al. (2000). Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. Annals of Otology, Rhinolology and Laryngology 182, 2-20.
9. Felmingham, D. & Grüneberg, R. N. (2000). The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 45, 191-203.
10. Hoban, D. J., Doern, G. V., Fluit, A. C., Roussel-Devallez, M. & Jones, R. N. (2001). Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clinical Infectious Diseases 32, Suppl. 2, S81-93.
11. Jones, R. N. (1999). The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory-tract infections. American Journal of Health-System Pharmacy 56, Suppl. 3, S4-11.
12. Felmingham, D. & Harding I. (2001). Telithromycin is highly active against clinical isolates of Streptococcus pneumoniae collected in the PROTEKT study, irrespective of penicillin, macrolide or fluoroquinolone resistance. Clinical Microbiology and Infection 7, Suppl. 1, Abstract P1253, p. 263.
13. Hyde, T. B., Gay, K., Stephens, D. S., Vugia, D. J., Pass, M., Johnson, S. et al. (2001). Macrolide resistance among invasive Streptococcus pneumoniae isolates. Journal of the American Medical Association 286, 1857-62.
14. Chen, D. K., McGeer, A., de Azavedo, J. C. & Low, D. E. (1999). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. New England Journal of Medicine 341, 233-9.
15. Granizo, J. J., Aguilar, L., Casal, J., García-Rey, C., Dal-Ré, R. & Baquero, F. (2000). Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (1979-1997). Journal of Antimicrobial Chemotherapy 46, 767-73.
16. Ball, P. (1999). Therapy for pneumococcal infection at the millennium: doubts and certainties. American Journal of Medicine 107, Suppl. 1A, 77S-85S.
17. Fogarty, C., Goldschmidt, R. & Bush, K. (2000). Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clinical Infectious Diseases 31, 613-5.
18. Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J., Kibsey, P. et al. (2002). Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 346, 747-50.
19. Garau, J. (2001). The clinical impact of macrolide resistance in pneumococcal respiratory infections. International Journal of Antimicrobial Agents 18, Suppl. 1, 33-8.
20. Jackson, M. A., Burry, V. F., Olson, L. C., Duthie, S. E. & Kearns, G. L. (1996). Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatric Infectious Disease Journal 15, 1049-51.
21. Kelley, M. A., Weber, D. J., Gilligan, P. & Cohen, M. S. (2000). Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clinical Infectious Diseases 31, 1008-11.
22. Metlay, J. P., Hofmann, J., Cetron, M. S., Fine, M. J., Farley, M. M., Whitney, C. et al. (2000). Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clinical Infectious Diseases 30, 520-8.
23. Musher, D. M., Dowell, M. E., Shortridge, V. D., Flamm, R. K., Jorgensen, J. H., Le Magueres, P. L. et al. (2002). Emergence of macrolide resistance during treatment of pneumococcal pneumonia. New England Journal of Medicine 346, 630-1.
24. Reid, R., Bradley, J. S. & Hindler, J. (1995). Pneumococcal meningitis during therapy of otitis media with clarithromycin. Pediatric Infectious Disease Journal 14, 1104-5.
25. Lonks, J. R., Garau, J., Gomez, L., Xercavins, M., Ochoa de Echaguen, A., Gareen, I. F. et al. (2002). Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 35, 556-64.
26. Bryskier, A., Agouridas, C. & Chantot, J. F. (1997). Ketolides: new semisynthetic 14-membered-ring macrolides. In Expanding Applications for the New Macrolides, Azalides and Streptogramins (Zinner, S. H., Young, L. S., Acer, J. F. & Neu, H. C., Eds), pp. 39-50. Marcel Dekker, New York, NY, USA.
27. Bryskier, A. (1999). New research in macrolides and ketolides since 1997. Expert Opinion on Investigational Drugs 8, 1171-94.
28. Bryskier, A., Agouridas, C. & Chantot, J. F. (1993). Acid stability of the new macrolides. Journal of Chemotherapy 5, Suppl. 1, 158-9.
29. B resistance phenotype. Journal of Antimicrobial Chemotherapy 40, 85-90.
30. Rosato, A., Vicarini, H., Bonnefoy, A., Chantot, J. F. & Leclerq, R. (1998). A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrobial Agents and Chemotherapy 42, 1392-6.
31. Champney, W. S. & Tober, C. L. (1999). Superiority of 11,12 carbonate macrolide antibiotics as inhibitors of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Current Microbiology 38, 342-8.
32. Douthwaite, S., Hansen, L. H. & Mauvais, P. (2000). Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Molecular Microbiology 36, 183-93.
33. Hansen, L. H., Mauvais, P. & Douthwaite, S. (1999). The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Molecular Microbiology 31, 623-31.
34. Barman Balfour, J. A. & Figgitt, D. P. (2001). Telithromycin. Drugs 61, 815-29.
35. Davies, T. A., Dewasse, B. E., Jacobs, M. R. & Appelbaum, P. C. (2000). In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 44, 414-7.
36. Leclercq, R. (2001). Safeguarding future antimicrobial options: strategies to minimize resistance. Clinical Microbiology and Infectious Diseases 7, Suppl. 3, 18-23.
37. Aubier, M., Aldons, P. M., Leak A., McKeith, D. D., Leroy, B., Rangaraju, M. et al. (2002). Telithromycin is as effective as amoxicillin/ clavulanate in acute exacerbations of chronic bronchitis. Respiratory Medicine 96, 862-71.
38. Buchanan, P., Stephens, T. & Leroy, B. (2003). A comparison of the efficacy of telithromycin vs cefuroxime axetil in the treatment of acute maxillary sinusitis. American Journal of Rhinology, in press.
39. Carbon, C., Moola, S., Velancsics, I., Leroy, B., Rangaraju, M. & De Costa, P. (2003). Efficacy of telithromycin, a new once-daily ketolide antimicrobial, in the treatment of community-acquired pneumonia. Clinical Microbiology and Infection, in press.
40. Tellier, G., Hassman, J., Leroy, B., Sidarous, E. & Youngblood, D. (2000). Oral telithromycin (HMR 3647; 800 mg od) is well tolerated and as effective as oral clarithromycin (500 mg bid) in community-acquired pneumonia (CAP) in adults. In Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 2227, p. 471. American Society for Microbiology, Washington, DC, USA.
41. Fogarty, C., Patel, T. C., Galbraith, H., Zuberbuhler, G. A. & Leroy, B., (2001). Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of adult patients with community-acquired pneumonia caused by Streptococcus pneumoniae. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001. Abstract 857, p. 449. American Society for Microbiology, Washington, DC, USA.
42. Hagberg, L., Torres, A., van Rensburg, D. J., Leroy, B., Rangaraju, M. & Ruuth, E. (2002). Efficacy and tolerability of once-daily therapy with telithromycin compared with high-dose amoxicillin for the treatment of community-acquired pneumonia. Infection 30, 378-86.
43. Roos, K., Brunswig-Pitschner, C., Kostrica, R., Pietola, M., Leroy, B., Rangaraju, M. et al. (2002). Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 48, 100-8.
44. van Rensburg, D. J., Matthews, P. A. & Leroy, B. (2002). Efficacy and safety of telithromycin in community-acquired pneumonia. Current Medical Research and Opinion 18, 397-400.
45. Grüneberg, R. N. & Felmingham, D. (1996). Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagnostic Microbiology and Infectious Disease 25, 169-81.
46. Douthwaite, S. (2001). Structure - activity relationships of ketolides vs. macrolides. Clinical Microbiology and Infection 7, Suppl. 3, 7-11.
47. Novotny, G. W., Andersen, N. M., & Douthwaite, S. (2001). Telithromycin interacts directly with the base of A752 in domain II of 23S ribosomal RNA, in contrast to erythromycin and clarithromycin. Clinical Microbiology and Infection 7, Suppl. 1, Abstract P480, p. 76.
48. Gay, K., Baughman, W., Miller, Y., Jackson, D., Whitney, C. G., Schuchat A. et al. (2000). The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based analysis. Journal of Infectious Diseases 182, 1417-24.
49. Peters, D. H., Friedel, H. A. & McTavish, D. (1992). Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44, 750-99.
50. Fine, M. J., Smith, M. A., Carson, C. A., Mutha, S. S., Sankey, S. S., Weissfield, L. A. et al. (1996). Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. Journal of the American Medical Association 275, 134-41.